JAMA Network
About The Study: Among patients discharged after hospitalization for heart failure (HF), de novo HF was associated with better clinical and patient-reported outcomes when compared with worsening chronic HF in this randomized clinical trial including 2,858 patients. Regardless of HF type, there was no significant difference between torsemide and furosemide with respect to 12-month clinical or patient-reported outcomes.
Authors: Selim R. Krim, M.D., of the Ochsner Clinic Foundation in New Orleans, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2023.4776)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
